RxDoctor Payments Data

Hilary Oakes, NP

Adult Health · Cheyenne, WYNPI 1699173161

Payments from drug & device makers

$2,908in general payments, 2019–2025

Across 114 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$745
  • Novartis$325
  • Abbott$273
  • Johnson & Johnson$214
  • AstraZeneca$170
  • Pfizer$163
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult health providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$22,435
Medicare patients
220
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$166,027
JardianceEmpagliflozin43$39,844
FarxigaDapagliflozin Propanediol49$35,262
EntrestoSacubitril/Valsartan20$18,785
XareltoRivaroxaban13$10,199
Metoprolol Succinate241$3,041
Atorvastatin Calcium224$2,577
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,578
Spironolactone159$1,082
Carvedilol109$836
Ezetimibe60$823
Losartan Potassium55$755
Potassium Chloride55$751
Amlodipine Besylate122$746
ClopidogrelClopidogrel Bisulfate63$676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$166,027167 claims
Boehringer IngelheimJardiance$108$39,84443 claims
AstraZenecaFarxiga$170$35,26249 claims
NovartisEntresto$325$18,78520 claims
Johnson & JohnsonXarelto$214$10,19913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult health providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other adult health in Cheyenne

Where these figures come from

Is this you, or does something look wrong? →